Greenwich Lifesciences Inc
GLSI11.940USD
+0.850+7.66%
Close 08/04, 16:00（ET）Quotes delayed by 15 min
157.52MMarket Cap
LossP/E TTM
More Details of Greenwich Lifesciences Inc Company
Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of GP2, immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the human epidermal growth factor receptor 2 (HER2)/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor to induce GP2 peptide-specific immunity. GP2 treatment is administered via an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. Its cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells while not affecting normal cells or to deliver immune system components to inhibit the spread of cancer. It has commenced a Phase III clinical trial, Flamingo-01 an immunotherapy to prevent breast cancer recurrences.
Company Info
Ticker SymbolGLSI
Company nameGreenwich Lifesciences Inc
IPO dateSep 25, 2020
CEOMr. Snehal Patel
Number of employees4
Security typeOrdinary Share
Fiscal year-endSep 25
Address3992 Bluebonnet Dr, Building 14
CitySTAFFORD
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code77477
Phone12034343290
Websitehttps://greenwichlifesciences.com
Ticker SymbolGLSI
IPO dateSep 25, 2020
CEOMr. Snehal Patel
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Snehal Patel
Mr. Snehal Patel
Chief Executive Officer, Chief Financial Officer, Director
Chief Executive Officer, Chief Financial Officer, Director
5.57M
+0.33%
Mr. David B. Mcwilliams
Mr. David B. Mcwilliams
Independent Chairman of the Board
Independent Chairman of the Board
620.33K
--
Mr. Kenneth Hallock
Mr. Kenneth Hallock
Independent Director
Independent Director
397.33K
--
Mr. Eric Rothe
Mr. Eric Rothe
Independent Director
Independent Director
313.25K
--
Dr. Jaye Thompson, Ph.D.
Dr. Jaye Thompson, Ph.D.
Vice President - Clinical & Regulatory Affairs
Vice President - Clinical & Regulatory Affairs
--
--
Dr. F. Joseph Daugherty, M.D.
Dr. F. Joseph Daugherty, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Snehal Patel
Mr. Snehal Patel
Chief Executive Officer, Chief Financial Officer, Director
Chief Executive Officer, Chief Financial Officer, Director
5.57M
+0.33%
Mr. David B. Mcwilliams
Mr. David B. Mcwilliams
Independent Chairman of the Board
Independent Chairman of the Board
620.33K
--
Mr. Kenneth Hallock
Mr. Kenneth Hallock
Independent Director
Independent Director
397.33K
--
Mr. Eric Rothe
Mr. Eric Rothe
Independent Director
Independent Director
313.25K
--
Dr. Jaye Thompson, Ph.D.
Dr. Jaye Thompson, Ph.D.
Vice President - Clinical & Regulatory Affairs
Vice President - Clinical & Regulatory Affairs
--
--
Dr. F. Joseph Daugherty, M.D.
Dr. F. Joseph Daugherty, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, May 16
Updated: Fri, May 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Patel (Snehal)
41.67%
McWilliams (David B)
4.64%
Hallock (Kenneth)
2.97%
BlackRock Institutional Trust Company, N.A.
2.41%
Rothe (Eric)
2.34%
Other
45.97%
Shareholders
Shareholders
Proportion
Patel (Snehal)
41.67%
McWilliams (David B)
4.64%
Hallock (Kenneth)
2.97%
BlackRock Institutional Trust Company, N.A.
2.41%
Rothe (Eric)
2.34%
Other
45.97%
Shareholder Types
Shareholders
Proportion
Individual Investor
54.28%
Investment Advisor
5.86%
Investment Advisor/Hedge Fund
2.35%
Hedge Fund
0.85%
Pension Fund
0.20%
Research Firm
0.15%
Bank and Trust
0.05%
Other
36.26%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
105
8.52M
63.74%
-338.41K
2025Q1
106
8.50M
64.50%
-388.04K
2024Q4
96
8.34M
63.41%
-410.99K
2024Q3
92
8.47M
64.65%
-203.33K
2024Q2
92
8.33M
64.66%
+241.77K
2024Q1
97
7.76M
60.42%
-184.06K
2023Q4
95
7.62M
59.30%
-311.10K
2023Q3
103
7.60M
59.17%
-679.19K
2023Q2
102
7.68M
59.81%
-652.02K
2023Q1
106
7.87M
61.24%
-314.63K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Patel (Snehal)
5.57M
41.67%
+18.10K
+0.33%
Apr 25, 2025
McWilliams (David B)
620.33K
4.64%
--
--
Apr 11, 2025
Hallock (Kenneth)
397.33K
2.97%
--
--
Apr 11, 2025
BlackRock Institutional Trust Company, N.A.
321.62K
2.41%
-5.91K
-1.81%
Mar 31, 2025
Rothe (Eric)
313.25K
2.34%
--
--
Apr 11, 2025
The Vanguard Group, Inc.
270.31K
2.02%
-4.68K
-1.70%
Mar 31, 2025
Thompson (Jaye L)
264.14K
1.98%
+1.00K
+0.38%
Nov 21, 2024
Geode Capital Management, L.L.C.
137.01K
1.02%
+2.94K
+2.19%
Mar 31, 2025
Daugherty (Frank Joseph)
90.13K
0.67%
--
--
Apr 11, 2025
DIM Funds SICAV S.A.
87.00K
0.65%
--
--
Jun 30, 2024
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0.01%
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
iShares Russell 2000 Growth ETF
0%
iShares Micro-Cap ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
